Heart failure & cardiomyopathiesSecondary analysis
Cardiac Biomarkers, Intensive Lifestyle Intervention, and Heart Failure Subtypes in Diabetes
- Secondary analysis of the Look AHEAD randomised trial
Authors' conclusion
In T2D, NT-proBNP can inform HF risk assessment and identify individuals who are more likely to benefit from an ILI.
Study context
- Population
- Adults with T2D and overweight or obesity in the Look AHEAD trial
- Participants
- 3,959 adults
- Comparison
- Intensive lifestyle intervention (ILI) vs diabetes support and education (DSE) across NT-proBNP categories
- Primary endpoint
- Risk of HF subtypes (heart failure with preserved ejection fraction (HFpEF): LVEF ≥50%; HFrEF: LVEF <50%) by baseline and 1-year change in NT-proBNP
Primary result
As reported in the abstract
HFpEF risk, ILI vs DSE, by NT-proBNP (subgroups)
ILI vs DSEHazard ratio (95% CI)
elevated baseline NT-proBNP (≥125 pg/mL)
0.47(0.24–0.90)
nonelevated baseline NT-proBNP
1.65(0.93–2.91)
stable or decreasing NT-proBNP at 1 year
0.58(0.34–0.99)
increasing NT-proBNP at 1 year
1.48(0.61–3.56)
Further findings
Heart failure with reduced ejection fraction (HFrEF) risk, ILI vs DSE, by NT-proBNP
- ILI not significantly associated with HFrEF risk across baseline or 1-year change NT-proBNP categories
Original publication
Cardiac Biomarkers, Intensive Lifestyle Intervention, and Heart Failure Subtypes in Diabetes. JACC Heart Fail. Published 7 November 2025. doi:10.1016/j.jchf.2025.102726
Summarised from the published abstract; every number is checked against it